Law360, New York (July 09, 2012, 6:22 PM ET) -- Dendreon Corp.'s executives have been hit with a shareholder derivative suit accusing them of withholding details about marketing issues concerning the firm's prostate cancer drug Provenge and causing a 67 percent stock drop when those problems were revealed, according to court documents made public Monday.
In a redacted complaint filed in Delaware state court, investor Herbert Silverberg accused the directors and officers of the Seattle-based biotechnology firm of cashing in on their knowledge of internal corporate information about doctors’ reluctance to administer the drug, allegedly selling...
Dendreon Execs Sued Over Sunny Cancer Drug Sales Forecasts
To view the full article, take a free trial now.
